Sandoz: Upgrading To A Buy On 2028 Expectations
Upgraded Sandoz from "hold" to "buy on dips" due to strong cash flow, promising growth in generics, and mid-term EBITDA margin guidance of 24-26% by 2028. Sandoz's 2024 revenue grew 4%, with a core EBITDA margin of 20.1%, generating $622M in free cash flow, or $1.45/share. Anticipated 2025 core EBITDA margin of 21% and projected 2028 EPS of $3.37, with a potential current value of 41 CHF/share.
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuilt offering, according to the bookrunner.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know
Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now
Sandoz Group AG Sponsored ADR (SDZNY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Sandoz Group AG Sponsored ADR (SDZNY) or Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks presents investors with the better value opportunity right now?
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those looking for undervalued stocks?
